Literature DB >> 27365079

Comparison of Blood Pressure Control Rates Among Recommended Drug Selection Strategies for Initial Therapy of Hypertension.

Kamel A Gharaibeh1, Stephen T Turner2, Abdurrahman M Hamadah2, Arlene B Chapman3, Rhonda M Cooper-Dehoff4, Julie A Johnson4, John G Gums4, Kent R Bailey5, Gary L Schwartz2.   

Abstract

BACKGROUND: Several approaches to initiation of antihypertensive therapy have been suggested. These include thiazide diuretics (TDs) as the first drug in all patients, initial drug selection based on age and race criteria, or therapy selection based on measures of plasma renin activity (PRA). It is uncertain which of these strategies achieves the highest control rate with monotherapy in Stage-I hypertension. We sought to compare control rates among these strategies.
METHODS: We used data from the Pharmacogenomic Evaluation of Antihypertensive Responses study (PEAR) to estimate control rates for each strategy: (i) TD for all, (ii) age- and race-based strategy: Hydrochlorothiazide (HCTZ) for all blacks and for whites ≥50 years and a renin-angiotensin system inhibitor (atenolol) for whites <50 years) or (iii) a PRA based strategy: HCTZ for suppressed PRA (<0.6ng/ml/h) and atenolol for non-suppressed PRA (≥0.6ng/ml/h) despite age or race. Hypertension was confirmed prior to treatment with HCTZ (148 blacks and 218 whites) or with atenolol (146 blacks and 221 whites).
RESULTS: In the overall sample, using clinic blood pressure (BP) response, the renin-based strategy was associated with the greatest control rate (48.9% vs. 40.8% with the age and race-based strategy (P = 0.0004) and 31.7% with the TD for all strategy (P < 0.0001)). The findings were similar using home or by 24-hour ambulatory BP responses and within each racial subgroup.
CONCLUSIONS: A strategy for selection of initial antihypertensive drug therapy based on PRA was associated with greater BP control rates compared to a thiazide-for-all or an age and race-based strategy. © American Journal of Hypertension, Ltd 2016. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  antihypertensive drug therapy; atenolol; beta-blocker; blood pressure; hydrochlorothiazide; hypertension; plasma renin activity; thiazide diuretic.

Mesh:

Substances:

Year:  2016        PMID: 27365079      PMCID: PMC5863787          DOI: 10.1093/ajh/hpw067

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  24 in total

Review 1.  Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review.

Authors:  Daniel A Duprez
Journal:  J Hypertens       Date:  2006-06       Impact factor: 4.844

Review 2.  Antihypertensive pharmacogenetics: getting the right drug into the right patient.

Authors:  S T Turner; G L Schwartz; A B Chapman; W D Hall; E Boerwinkle
Journal:  J Hypertens       Date:  2001-01       Impact factor: 4.844

Review 3.  Oral renin inhibitors.

Authors:  Jan A Staessen; Yan Li; Tom Richart
Journal:  Lancet       Date:  2006-10-21       Impact factor: 79.321

4.  Responses to captopril and hydrochlorothiazide in black patients with hypertension.

Authors:  M Moser; J Lunn
Journal:  Clin Pharmacol Ther       Date:  1982-09       Impact factor: 6.875

5.  Blood pressure regulation: basic concepts.

Authors:  A C Guyton; J E Hall; T E Lohmeier; T E Jackson; P R Kastner
Journal:  Fed Proc       Date:  1981-06

6.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

Review 7.  Medication nonadherence: an unrecognized cardiovascular risk factor.

Authors:  Mark A Munger; Benjamin W Van Tassell; Joanne LaFleur
Journal:  MedGenMed       Date:  2007-09-19

8.  Plasma renin activity and plasma prorenin assays.

Authors:  J E Sealey
Journal:  Clin Chem       Date:  1991-10       Impact factor: 8.327

9.  Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study.

Authors:  Julie A Johnson; Eric Boerwinkle; Issam Zineh; Arlene B Chapman; Kent Bailey; Rhonda M Cooper-DeHoff; John Gums; R Whit Curry; Yan Gong; Amber L Beitelshees; Gary Schwartz; Stephen T Turner
Journal:  Am Heart J       Date:  2009-03       Impact factor: 4.749

10.  Plasma renin and "prorenin" in essential hypertension during sodium depletion, beta-blockade, and reduced arterial pressure.

Authors:  S A Atlas; J E Sealey; J H Laragh; C Moon
Journal:  Lancet       Date:  1977-10-15       Impact factor: 79.321

View more
  3 in total

1.  Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension.

Authors:  Mai Mehanna; Yan Gong; Caitrin W McDonough; Amber L Beitelshees; John G Gums; Arlene B Chapman; Gary L Schwartz; Julie A Johnson; Stephen T Turner; Rhonda M Cooper-DeHoff
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-09-21       Impact factor: 3.738

2.  Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.

Authors:  Mai Mehanna; Zhiying Wang; Yan Gong; Caitrin W McDonough; Amber L Beitelshees; John G Gums; Arlene B Chapman; Gary L Schwartz; Kent R Bailey; Julie A Johnson; Stephen T Turner; Rhonda M Cooper-DeHoff
Journal:  Am J Hypertens       Date:  2019-06-11       Impact factor: 3.080

3.  Optimizing Precision of Hypertension Care to Maximize Blood Pressure Control: A Pilot Study Utilizing a Smartphone App to Incorporate Plasma Renin Activity Testing.

Authors:  Mai Mehanna; Yiqing E Chen; Yan Gong; Eileen Handberg; Brittney Roth; Jessica De Leon; Steven M Smith; Jonathan G Harrell; Rhonda M Cooper-DeHoff
Journal:  Clin Transl Sci       Date:  2020-11-30       Impact factor: 4.689

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.